Expression across solid cancers makes TF an interesting therapeutic cancer target, and preclinical proof‐of‐concept studies have been described for TF‐targeting antibodies, antibody‐drug conjugates, immune‐conjugates, micro‐RNAs, and TF pathway inhibitors.9, 14, 15. This evidence concerns the gene TF and cancer.